Is Milestone Pharmaceuticals, Inc. overvalued or undervalued?
As of May 13, 2024, Milestone Pharmaceuticals, Inc. is considered overvalued and has been downgraded to "does not qualify" due to negative financial metrics, including a Price to Book Value of -15.11 and a year-to-date return of -25.42%, significantly underperforming compared to the S&P 500.
As of 13 May 2024, the valuation grade for Milestone Pharmaceuticals, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently considered overvalued, reflected by its negative Price to Book Value of -15.11 and EV to EBITDA of -1.76. Additionally, the ROE is negative due to a lack of positive book value, further emphasizing the company's financial struggles.In comparison to its peers, Milestone's EV to EBIT ratio of -1.74 stands out against Eton Pharmaceuticals, Inc. with a ratio of -92.8956, and Abeona Therapeutics, Inc. at -4.5154, both of which are also classified as risky. The stark negative ratios across the board suggest that the company is not generating value relative to its peers. Despite a recent uptick in stock price, Milestone's year-to-date return of -25.42% compared to the S&P 500's 2.44% reinforces the notion that it is not a favorable investment at this time.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
